With the rise in chronic diseases, increased investment and rising prices of pharmaceuticals, it may be a smart move to acquire shares of low quality but cheap pharmaceutical stocks Vertex Pharmaceuticals and Takeda Pharmaceutical. These names are both down over 20% since last year. Continue reading. The pharmaceutical industry continues to draw increased investor attention because of the increasing prevalence of chronic disease, an aging population and large investments. Investors’ interest in this space is evidenced by the Invesco Dynamic Pharmaceuticals ETF’s (PJP) 5% returns over the past month, and 12.8% gains year-to-date.

Globally, governments have been increasing their focus on pharmaceutical research and development. As part of President Biden’s Build back Better social spending plan, the U.S. Democrats have been considering cutting prescription drug costs for senior Americans. A Linchpin report also predicts that the global pharmaceutical industry will reach $1.50 trillion in 2023.

Therefore, we think it could be wise to add fundamentally sound pharmaceutical stocks Vertex Pharmaceuticals Incorporated (VRTX) and Takeda Pharmaceutical Company Limited (NYSE:) to one’s portfolio now. The stock has seen an increase in value of over 20% and is trading at significant discount to its peers.

Continue reading on StockNews